Complicated Urinary Tract Tuberculosis in a 13-Year-Old Adolescent with Chronic Kidney Disease and Antituberculous Drug-Induced Hepatotoxicity

Heda Melinda Nataprawira 1, Adhitya Agung Pratama 2, Ahmedz Widiasta 2, Jupiter Sibarani 3, Dany Hilmanto 2, Nanan Sekarwana 2, and Dedi Rachmadi 2

1Respirology Division, Department of Child Health, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Pasteur 38, Bandung, West Java 40161, Indonesia
2Nephrology Division, Department of Child Health, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Pasteur 38, Bandung, West Java 40161, Indonesia
3Urology Department, Department of Child Health, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Pasteur 38, Bandung, West Java 40161, Indonesia

Correspondence should be addressed to Ahmedz Widiasta; ahmedzwidiasta@gmail.com

Received 24 January 2019; Accepted 29 August 2019; Published 23 October 2019

1. Introduction

Tuberculosis (TB) is still a burden of social health in the world according to the World Health Organization (WHO) report. Indonesia is in the second position on the list of TB patients globally. The World Health Organization Global Report 2017 declared that extrapulmonary TB accounted for 15% of all TB cases in the world. Urinary tract TB is a rare case in children, represents less than 5% of pediatric extrapulmonary TB [1, 2]. Tuberculosis in younger children is the most challenging, especially in countries with limited resources and high endemicity like ours. The urinary tract TB is potentially underdiagnosed because of the nonspecific urinary tract symptoms such as urethral stricture, contracted bladder, and even chronic kidney disease [3–6]. Urinary tract TB has a wide spectrum of symptoms, but the most common is pain on micturition and hematuria [2]. Gold standard for the diagnosis of urinary tract TB is established through the isolation and culture of Mycobacterium tuberculosis [1]. Early diagnosis of urinary tract TB could prevent the sequelae such as kidney impairment [1, 3–5]. In this report, we also evaluated a stunted school girl who presented with complain in micturition.
2. Case Report

A 13-year-old girl from a remote village of Bandung presented with urology emergency to our hospital with gross hematuria and difficult and painful micturition since 2 years before admission. She had flank pain as well since a year ago. There was no history of cough, night sweats, malaise, or swelling of abdomen or extremities. The patient had lost her weight for about 2 kg in a month. There was no history of TB disease previously, but her grandmother was diagnosed as having pulmonary TB and was on TB treatment.

Physical examination showed undernourishment, body weight 27 kg (–2 to –3SD), and height 137 cm (–2 to –3SD). On examination, her general appearance was moderately ill and blood pressure was within the normal limit and had no fever. There was pain on the left flank. Urine microscopy showed leukocyturia, hematuria, and positive acid-fast bacilli, and *M. tuberculosis* was detected in rapid-test molecular test (gene Xpert). Laboratory findings showed serum creatinine 0.80 mg/dL, serum urea 12.0 mg/dL, serum sodium 142 mEq/L, serum potassium 4.5 mEq/L, serum calcium 5.61 mg/dL, Hb 10.6 g/dL, hematocrit 33.9%, WBC 11,800/mm³, platelet count 663,000/mm³, differential count 0/2/0/5/6, and quantitative CRP 1.2 mg/dL, and anti-HCV, anti-HIV, anti-HCV, and HbsAg were negative. Ultrasound of kidney-ureter-bladder showed bilateral kidney pelvocaliectasis, and diuretic renogram revealed an important difference in renal function, i.e., the uncorrected glomerular filtration rate (GFR) of the right kidney and the left kidney was 32.5 mL/min/1.73 m² and 5 mL/min/1.73 m², respectively. Chest radiograph showed active pulmonary tuberculosis; Mantoux test showed positive result (an induration of 17 mm). Based on those findings, we diagnosed complicated urinary tract infection, left ureteral stenosis, bilateral hydronephrosis, and stage 3 chronic kidney disease (CKD). Left kidney nephrectomy and bladder augmentation were performed by a pediatric urologist, and then the anatomopathological result was pyelonephritis tuberculosis (tuberculoma).

The patient was treated with four antituberculous drugs in the intensive phase which she had completed and then continued with two antituberculous drugs in the continuation phase. She experienced antituberculous drug-induced hepatotoxicity (ADIH) after two months of antitubercular treatment (ATT). We diagnosed the patient as complicated urinary tract TB, stage 3 chronic kidney disease (CKD), and ADIH. The patient was given ethambutol and streptomycin with an adjusting dose according to GFR and was given calcium carbonate, folic acid, and vitamin D orally. The child gained 2.5 kilograms during this time period, and her condition improved significantly (Figure 1).

The patient was discharged in good condition, without any hypertension and other chronic kidney disease symptoms; the GFR was 29.5 mL/min/1.73 m² and bladder capacity was 250–300 mL after having bladder augmentation. Her quality of life was gradually getting better according to the pediatric symptoms checklist for quality of life (PedsQL) of patient age 13–18 years old, and she can perform some daily activity well without any physical and psychological disturbances.

![Figure 1: Photomicrograph (H and E x400) showing a multinucleated giant cell that is characteristic of tuberculoma.](image-url)
age of the 17 children was in the range of 7–13 years [3–5, 7, 11–13].

Arora et al. reported three case reports in India, one of them with symptoms and signs which resemble our patient. The patient was a 13-year-old boy, presented with fever, hematuria, burning micturition, massively proteinuria, and cervical lymphadenopathy. The Mantoux test was strongly positive. Chest radiograph presented right hilar lymphadenopathy, and ultrasonography showed evidence of acute pyelonephritis. The fine-needle aspiration cytology (FNAC) result established tuberculous lymphadenitis, and he responded to ATT. Follow-up urinalysis and ultrasound were normal [13, 14].

This case has an earlier age than the previous reports, and the symptoms resemble with other complicated urinary tract infection, so it was very difficult to make urinary tract tuberculosis diagnosis without histopathologic examination.

Approximately, 25% of tuberculosis cases might affect extrapulmonary organs through hematogenous and lymphatic spread [1]. Urinary tract tuberculosis is one of the rare manifestations of Mycobacterium tuberculosis (MTB) infections [1].

The incidence rate is less than 5% of all tuberculosis manifestations [3]. The common symptoms are pain on the abdomen, waist, and lower back or difficult micturition [3]. Systemic symptoms such as fever, weight loss, and decreased appetite are rarely complained [3]. The symptom in these patients was difficult and painful micturition that has been felt since two years before admission [15–19].

Urinalysis might show hematuria and pyuria with sterile urine culture results. Acid-fast bacilli (AFB) could also be detected in 80–90% of cases of urinary tract tuberculosis. Examination of the urine culture usually takes a long time, which is about 6–8 weeks, and the probability of false-negative results is 10–20% [19].

Urinary tract tuberculosis resulting from hematogenous spread begins with the formation of primary tuberculosis focus [1, 3, 4, 20]. Mycobacterium tuberculosis has a high resistance to the destruction process, so that the bacteria duplicate in the macrophages and then carry into the lymphatic and hematogenous flow by bringing macrophages that contain the bacteria throughout the body until it ends in the kidney [1]. Selective immunity will form and inhibit multiplication of bacteria and retain it in the macrophages by forming microscopic granulomas [21–26].

Granulomas will eradicate or trap the bacteria for several years in the good immunity state. Differently, with the immunocompromised state, they might reactivate or reinf ect, and one or two tubercles might become enlarged after several years of inactivity [1]. This inactive period may last from 5 to 40 years [1]. Mycobacterium tuberculosis is locked in the periglomerular capillaries of the kidney developed into macroscopic granuloma [1]. Some granulomas then became enlarged and united, with the inner tuberculosis bacillus filling the nephron and reach the small part of the loop of Henle, forming the focus of infection within the kidney pyramid [1]. These papillary lesions merge and form the “ulcero-cavernous” lesion that ends in the pelvicalyceal system [1, 3, 4]. Extensive papillary necrosis develops and forms a cavity and then destroys the kidney parenchyma [1].

At an advanced stage, the disease induces scars on the kidney cortex resulting in infundibular and pelvoureteral junction stenosis which would result in decreased function because of the extensive calcification that involves the entire kidney [1, 3, 4]. The young age and malnourished condition of our patient are predisposing factors for the reactivation for tuberculosis [6, 20, 21, 24].

Acid-fast bacilli (AFB) examination in the urine with Ziehl–Neelsen staining should be checked 3 times in a row, but its sensitivity is very low (40%) although its specificity is high (96.7%), with the positive result only when 5,000–10,000 bacteria/mL urine is present. In these patients, urinalysis yielded positive results on the first examination. Sample culture is a gold standard for TB diagnosis with a high sensitivity and specificity, 94.3% and 85.7%, respectively. The culture yields positive results when there is ≥10 bacteria/mL urine. These patients were subjected to culture examination without growth of microorganisms [19]. The positive paraclinical finding in this patient was kidney abnormalities revealed on ultrasound and intravenous pyelography as bilateral pelvicaliectasis, contracted bladder, and left ureteral stenosis which are the common changes reported in urinary tract tuberculosis. Pathology anatomical findings identified tubercle formation consisting of caseating necrosis, epitheloid proliferation, and multinucleated giant cells (datia langhans cells). Our suggestion is that the TB infection began and made some inflammatory process from bladder then ascended to the ureter and the kidney.

Treatment of urinary tract tuberculosis has two options: medical management and operative procedure. Tuberculosis of the kidneys is a severe tuberculosis of the weight category, and the management of anti-TB treatment is included in category I, with at least 4 kinds of drugs in the first 2 months isoniazid (H), rifampicin (R), pyrazinamide (Z), and ethambutol (E) or (2HRZE), followed by 2 kinds of drugs (4HR). Treatment for 6 months is recommended for tuberculosis involving all extrapulmonary organs, except those involving meninges requiring treatment for 9–12 months. Extension of the treatment should also be considered for extrapulmonary slow response TB patients [6, 9, 27, 28].

If patients had impaired kidney function, then the safe antituberculous options are isoniazid, rifampicin, and pyrazinamide. These drugs may be administered in normal doses because they are eliminated in the bile, and they are not excreted in the kidney. Streptomycin, ethambutol, and aminoglycosides are nephrotoxic; however, streptomycin and ethambutol could still be administered by adjusting the dose with the glomerular filtration rate (GFR) [21].

Most of the first-line ATT drugs are isoniazid, rifampicin, and pyrazinamide, which have a high incidence rate of hepatotoxicity. Treatment is needed to eliminate tuberculosis, but this action will further increase the potential for toxicity to the liver. When ADIH occurs in the patient, it would reduce the efficacy of the first-line drugs, thereby lengthening the duration of the treatment and increasing the risk of treatment failure [23]. Treating TB with kidney impairment (CKD) and liver disease (ADIH) is very challenging. The patient had a difficult condition because she could not be treated adequately as she had ADIH. We
change the ATT with ethambutol and streptomycin with dose adjusted with her GFR. Treatment of ADIH is immediate cessation of antituberculous drugs and supportive treatment. Earlier, children receiving antituberculosis treatment should be evaluated to assess treatment success, adherence, and monitoring of adverse drug effects. When there was an increase in the transaminase levels ≥2 times the normal value, aspartate serum transaminase (AST) monitoring is required every week for 2 weeks and then every 2 weeks until it returns to normal [16, 20, 24].

Several countries have their own guidance on dealing with ADIH diseases, such as ATS, the Centers for Disease Control (CDC), and BTS, that issued adult guidelines for monitoring and evaluation of treatments on ADIH, such as liver function examination during antituberculosis administration, diagnosis, and how antituberculosis drug reintroduce to ADIH. In order to find the appropriate monitoring schedule for ADIH patients, they conducted a study and concluded the importance of liver function audit data prior to antituberculosis treatment [20, 23–25].

Beside the medical management, we also performed surgical management. We performed nephrectomy of the left kidney and bladder augmentation because bladder TB usually results in patchy cystitis due to inflammation of the uroepithelium by the tubercle bacillus. Resultant granulomatous inflammation, caseation necrosis, and final healing by fibrosis may lead to marked contracture of the urinary bladder within a year. There are two types of lesions in the tubercular bladder: One, (the most common form) when the bladder has reduced its capacity about 150–200 mL. The other type is structural bladder contracture wherein the urinary bladder has permanently lost its capacity and has little or no value as a urinary reservoir [29]. The ileum provides an excellent pouch to enlarge the bladder capacity when only half of the bladder is planned to be removed [30].

Good collaboration between medical and surgical treatment delivers better quality of life.

Conflicts of Interest
The authors declare that there are no financial and personal relationships with other people or organizations that could inappropriately influence their work.

Authors’ Contributions
Heda Melinda Nataprawira conceptualized and designed the study and was involved in data acquisition, analysis of data, drafting the manuscript, and critical revision. Adhiyia Agung Pratama, Ahmedz Widiasta, Dedi Rachmadi, Dany Hilmantri, and Nanan Sekarwana were involved in data acquisition, analysis of data, and critical revision. Jupiter Sibarani operated the patient and was involved in analysis of data and critical revision.

References
[1] H. M. Nataprawira, R. A. Hannah, and H. H. Kartika, "Hospitalized pediatric antituberculosis drug induced hepatotoxicity: experience of an Indonesian referral hospital," Asian Pacific Journal of Tropical Disease, vol. 7, no. 5, pp. 276–279, 2017.
[2] R. D. Feigin, J. D. Cherry, G. J. Demmler, and S. L. Kaplan, Textbook of Pediatric Infectious Diseases, Saunders, Philadelphia, PA, USA, 1981.
[3] WHO, Global Tuberculosis Report 2017, WHO, Geneva, Switzerland, 2017.
[4] A. Abbara, S. Chitty, J. K. Roe et al., "Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK," BMC Infectious Diseases, vol. 17, no. 1, p. 231, 2017.
[5] V. Ramappa and G. P. Aithal, "Hepatotoxicity related to antituberculosis drugs: mechanisms and management," Journal of Clinical and Experimental Hepatology, vol. 3, no. 1, pp. 37–49, 2013.
[6] S. D. Gupta, P. Das, and A. Ahuja, “Incidence, etiopathogenesis and pathological aspects of genitourinary tuberculosis in India: a journey revisited," Indian Journal of Urology, vol. 24, no. 3, p. 356, 2008.
[7] W. Abera, W. Cheneke, and G. Abebe, “Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: a cohort study," International Journal of Mycobacteriology, vol. 5, no. 1, pp. 14–20, 2016.
[8] A. Wallgren, "The time-table of tuberculosis," Tubercle, vol. 29, no. 11, pp. 245–251, 1948.
[9] E. Kulchavenya, "Best practice in the diagnosis and management of urogenital tuberculosis," Therapeutic Advances in Urology, vol. 5, no. 3, pp. 143–151, 2013.
[10] J. Harambat, K. J. Van Stralen, J. J. Kim, and E. J. Tizard, “Epidemiology of chronic kidney disease in children," Pediatric Nephrology, vol. 27, no. 3, pp. 363–373, 2012.
[11] A. A. Figueiredo, A. M. Lucon, C. M. Gomes, and M. Srougi, “Urogenital tuberculosis: patient classification in seven different groups according to clinical and radiological presentation," International Journal of Mycobacteriology, vol. 34, no. 4, pp. 422–432, 2008.
[12] J. J. Saukkonen, D. L. Cohn, R. M. Jasmer et al., "An official ATS statement: hepatotoxicity of antituberculosis therapy," American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 8, pp. 935–952, 2006.
[13] W. W. Yew and C. C. Leung, “Antituberculosis drugs and hepatotoxicity," Respiratory, vol. 11, no. 6, pp. 699–707, 2006.
[14] N. Arora, A. Sahu, and M. Kaur, "Tuberculous pyelonephritis in children: three case reports," Paediatrics and International Child Health, vol. 37, no. 4, pp. 292–297, 2017.
[15] H. Devarbhavi, "Antituberculous drug-induced liver injury: current perspective," Tropical Gastroenterology, vol. 32, no. 3, pp. 167–174, 2011.
[16] Joint Tuberculosis Committee of the British Thoracic Society, "Control and prevention of tuberculosis in the United Kingdom: code of practice 2000," Thorax, vol. 55, no. 11, pp. 887–901, 2000.
[17] S. Agal, R. Baijal, S. Pramanik et al., “Monitoring and management of antituberculosis drug induced hepatotoxicity," Journal of Gastroenterology and Hepatology, vol. 20, no. 11, pp. 1745–1752, 2005.
[18] S. K. Sharma, R. Singla, P. Sarda et al., “Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity," Clinical Infectious Diseases, vol. 50, no. 6, pp. 833–839, 2010.
[19] C. Duicu, O. Marginean, E. Kiss, L. Lörinczi, and C. Banescu, "Genitourinary tuberculosis in children: a diagnostic
challenge,” *Romanian Review of Laboratory Medicine*, vol. 21, no. 3, pp. 301–309, 2013.

[20] J. B. Eastwood, C. M. Corbishley, and J. M. Grange, “Tuberculosis and the kidney,” *Journal of the American Society of Nephrology*, vol. 12, no. 6, pp. 1307–1314, 2001.

[21] A. F. Mayans, O. A. Feu, H. A. Til et al., “Renal tuberculosis in a 9 months old: case report and review of the literature,” *Urology Case Reports*, vol. 13, pp. 104–106, 2017.

[22] F. Guarino, A. Martínez-Roig, J. Maiques-Llacer, M. Á. González-Rivero, and O. Anguerri-Feu, “Renal tuberculosis in a thirteen-month-old female infant,” *The Pediatric Infectious Disease Journal*, vol. 28, no. 8, pp. 757-758, 2009.

[23] A. Dhua, N. Borkar, V. Ghosh, and S. Aggarwal, “Renal tuberculosis in infancy,” *Journal of Indian Association of Pediatric Surgeons*, vol. 16, no. 2, p. 69, 2011.

[24] S. Merchant, A. Bharati, and N. Merchant, “Tuberculosis of the genitourinary system-urinary tract tuberculosis: renal tuberculosis-part I,” *Indian Journal of Radiology and Imaging*, vol. 23, no. 1, p. 46, 2013.

[25] R. B. Nerli, G. V. Kamat, S. B. Alur, A. Koura, P. Vikram, and S. S. Amarkhed, “Genitourinary tuberculosis in pediatric urological practice,” *Journal of Pediatric Urology*, vol. 4, no. 4, pp. 299–303, 2008.

[26] E. D. F. Daher, E. J. G. Barros, and G. B. da Silva Junior, “Renal tuberculosis in the modern era,” *The American Journal of Tropical Medicine and Hygiene*, vol. 88, no. 1, pp. 54–64, 2013.

[27] E. Kulchavenya, “Urogenital tuberculosis--definition and classification,” in *Current Therapy and Surgery for Urogenital Tuberculosis*, pp. 31–49, Springer, Berlin, Germany, 2016.

[28] M. Çek, S. Lenk, K. G. Naber et al., “EAU guidelines for the management of genitourinary tuberculosis,” *European Urology*, vol. 48, no. 3, pp. 353–362, 2005.

[29] J. G. Gow and S. Barbosa, “Genitourinary tuberculosis: a study of 1117 cases over a period of 34 years,” *BJU International*, vol. 56, pp. 449–455, 1984.

[30] F. A. Duff, J. F. O’Grady, and D. G. Kelly, “Colocystoplasty: a review of 10 cases1,” *British Journal of Urology*, vol. 42, no. 6, pp. 704–713, 1970.